Northern Trust’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-436,866
| Closed | -$32.9M | – | 4803 |
|
|
2022
Q2 | $32.9M | Buy |
436,866
+414
| +0.1% | +$18.4K | 0.01% | 1181 |
|
|
2022
Q1 | $11.7M | Sell |
436,452
-8,639
| -2% | -$290K | ﹤0.01% | 2046 |
|
|
2021
Q4 | $21.2M | Sell |
445,091
-178,790
| -29% | -$7.99M | ﹤0.01% | 1726 |
|
|
2021
Q3 | $41.4M | Sell |
623,881
-12,533
| -2% | -$893K | 0.01% | 1235 |
|
|
2021
Q2 | $49.7M | Buy |
636,414
+215,525
| +51% | +$15.9M | 0.01% | 1145 |
|
|
2021
Q1 | $39.8M | Sell |
420,889
-17,223
| -4% | -$2.05M | 0.01% | 1303 |
|
|
2020
Q4 | $53.4M | Buy |
438,112
+33,164
| +8% | +$3.63M | 0.01% | 1024 |
|
|
2020
Q3 | $35.4M | Buy |
404,948
+67,821
| +20% | +$4.72M | 0.01% | 1159 |
|
|
2020
Q2 | $21.8M | Buy |
337,127
+35,847
| +12% | +$2.07M | 0.01% | 1549 |
|
|
2020
Q1 | $13.5M | Buy |
301,280
+1,541
| +0.5% | +$81.8K | ﹤0.01% | 1690 |
|
|
2019
Q4 | $18.7M | Buy |
299,739
+192,681
| +180% | +$9.17M | ﹤0.01% | 1776 |
|
|
2019
Q3 | $4.03M | Buy |
107,058
+69,506
| +185% | +$3.03M | ﹤0.01% | 2672 |
|
|
2019
Q2 | $1.53M | Buy |
+37,552
| New | +$1.34M | ﹤0.01% | 3201 |
|
Northern Trust's TPTX Position: Q3 2022 in Review
Northern Trust sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 436,866 shares — an estimated $32.9M sold.
Northern Trust first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $53.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Northern Trust reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Northern Trust sold 436,866 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $32.9M.
- Northern Trust first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Northern Trust's Turning Point Therapeutics, Inc. Common Stock position peaked at $53.4M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Northern Trust's 13F filing for Q3 2022, filed 14 Nov 2022.